Abstract:Ziqin Zhao, 1 Shuhui Dong, 1 Yong Yang, 1 Haibo Yin, 1 Guangyi Xiong, 1 Jianxiong Ma 2 1 Department of Pathology, Tianjin Hospital, Tianjin University, Tianjin, People's Republic of China; 2 Institute of Orthopaedic Surgery, Tianjin Hospital, Tianjin University, Tianjin, People's Republic of China Correspondence: Jianxiong Ma, Institute of Orthopaedic Surgery, Tianjin Hospital, Tianjin University, Tianjin, People's Republic of China, Email Introduction: Chondrocyte degeneration and senescence are characteristics of osteoarthritis (OA) and other joint degenerative diseases, and ferroptosis has been observed to regulate the development of OA. However, the role of the N 6 -methyladenosine (m 6 A) modification in OA ferroptosis remains unclear. Methods: This study performed series of assays to investigate the function of the m 6 A reader IGF2BP1 in OA ferroptosis, including m 6 A quantitative analysis, Iron (Fe 2+ ) release analysis, Malondialdehyde (MDA) measurement, lipid peroxidation (ROS) detection and Glutathione (GSH) measurement. The molecular interaction and mechanism analysis was performed by Luciferase reporter assay, mRNA stability analysis and RNA immunoprecipitation (RIP) assay. Results: These results indicate that IGF2BP1 is upregulated in IL-1β-induced chondrocytes. Functionally, IGF2BP1 silencing represses ferroptosis, including iron (Fe 2+ ) accumulation, malondialdehyde, and reactive oxygen species (ROS). Mechanistically, among the potential downstream targets, matrix metalloproteinase-3 (MMP3) was observed to harbor a significant m 6 A modified site in the 3'-UTR. IGF2BP1 combines with MMP3 through the binding of m 6 A sites, thereby enhancing MMP3 mRNA stability. Discussion: In conclusion, our findings revealed the functions and mechanisms of m 6 A regulator IGF2BP1 in OA chondrocyte's ferroptosis, providing a novel target for OA treatment. Keywords: osteoarthritic cartilage, IGF2BP1, ferroptosis, MMP3 Osteoarthritis (OA) is the most common musculoskeletal disease and is associated with an extremely high disability rate and a decreased quality of life in the elderly population. 1 The clinical symptoms of OA include joint swelling, joint stiffness, joint pain, and loss of joint function, which induce difficulties in daily activities. 2 Currently, there are few effective treatments for OA other than total knee replacement in patients with advanced OA. 3 For patients with early OA, the treatment is to reduce joint wear and relieve pain. 4 Furthermore, nonsteroidal anti-inflammatory drugs and surgical interventions are also applied to OA treatment, which have some side effects. 5 Therefore, it is necessary to identify novel molecular targets for OA pathophysiology and prevention. N 6 -methyladenosine (m 6 A) is an important ubiquitous internal modification of eukaryotic RNA that plays a critical role in physiological functions. 6 The m 6 A modification has been shown to modify numerous aspects of pathophysiological processes, including RNA metabolism, export, translation, and decay. Three key enzymes regulate the m 6 A modification, including "writer" proteins (METTL3, METTL14, KIAA1429, WTAP, etc.), "eraser" proteins (ALKBH5, FTO) and "reader" proteins (YTHDF1/2/3 YTHDC1, IGF2BP1/2/3, etc.). In OA pathophysiology, m 6 A levels in clinical OA samples are higher than those in healthy samples. 7 Currently, key m 6 A modification enzymes are known to act as risk factors for OA, or might provide potential therapeutic targets for OA treatment. For example, METTL3 is highly expressed in clinical samples from patients with OA, and low METTL3 expression inhibits chondrocyte pyroptosis. 7 Ferroptosis is an iron-dependent subtype of programmed cell death (iron-dependent type) involved in oxidative stress-induced cell death. 8–10 Several studies have demonstrated that redox imbalance plays an important role in OA development. Previous studies have indicated that iron can trigger bovine articular cartilage degeneration by enhancing the release of sulfated glycosaminoglycan. For example, chondrocytes undergo inflammation and iron overload that can trigger ferroptosis. Recent findings have indicated that ferroptosis plays an important role in the occurrence and development of OA. For instance, the ferroptosis-related genes LPCAT3 and PGD, which have both been identified as effective diagnostic biomarkers for OA patients, are decreased in OA chondrocytes with an IL-1β-induced condition. 11 There was remarkable rele -Abstract Truncated-

METTL14 promotes chondrocyte ferroptosis in osteoarthritis via m6A modification of GPX4

Contribution of ferroptosis and GPX4’s dual functions to osteoarthritis progression

Chondroprotective effects of bone marrow mesenchymal stem cell-derived exosomes in osteoarthritis

METTL14-Mediated m6A Modification of TUG1 Represses Ferroptosis in Alzheimer's Disease via Inhibiting GDF15 Ubiquitination

IGF2BP1 Bolsters the Chondrocytes Ferroptosis of Osteoarthritis by Targeting m6A/MMP3 Axis

M7g-Modified Mt-Trf3b-leutaa Regulates Mitophagy and Metabolic Reprogramming Via SUMOylation of SIRT3 in Chondrocytes

OGT promotes the ferroptosis of chondrocytes in osteoarthritis development via O-GlcNAcylation modification of ACSF2

GPX7 reduces chondrocyte inflammation and extracellular matrix degradation triggered by IL‐1β, via a mechanism mediated by ferroptosis

Methyltransferase-like 3 silenced inhibited the ferroptosis development via regulating the glutathione peroxidase 4 levels in the intracerebral hemorrhage progression

Gossypol Acetic Acid alleviates the Ferroptosis of Chondrocytes in Osteoarthritis by Inhibiting GPX4 Methylation

SCP2 Mediates the Transport of Lipid Hydroperoxides to Mitochondria in Chondrocyte Ferroptosis

SCD1 deficiency exacerbates osteoarthritis by inducing ferroptosis in chondrocytes

METTL3-mediated M6a Modification of ATG7 Regulates Autophagy-Gata4 Axis to Promote Cellular Senescence and Osteoarthritis Progression.

PPARγ Activation Suppresses Chondrocyte Ferroptosis Through Mitophagy in Osteoarthritis

Single cell RNA-seq analysis identifies ferroptotic chondrocyte cluster and reveals TRPV1 as an anti-ferroptotic target in osteoarthritis

The RNA-binding protein SND1 promotes the degradation of GPX4 by destabilizing the HSPA5 mRNA and suppressing HSPA5 expression, promoting ferroptosis in osteoarthritis chondrocytes

Moderate mechanical stress suppresses chondrocyte ferroptosis in osteoarthritis by regulating NF-κB p65/GPX4 signaling pathway

Glutathione peroxidase 4 restrains temporomandibular joint osteoarthritis progression by inhibiting ferroptosis

METTL3-mediated m 6 A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression

P21 resists ferroptosis in osteoarthritic chondrocytes by regulating GPX4 protein stability

KLF2 Inhibits Ferroptosis and Improves Mitochondrial Dysfunction in Chondrocyte Through SIRT1/GPX4 Signaling to Improve Osteoarthritis